Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Acquisitions & Divestments (2016 - 2021)

IGC Pharma (IGC) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with -$3.0 million as the latest value for Q1 2021.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to -$3.0 million in Q1 2021 year-over-year; TTM through Mar 2022 was -$1.2 million, a 0.2% change, with the full-year FY2021 number at $47000.0, changed N/A from a year prior.
  • Change in Acquisitions & Divestments was -$3.0 million for Q1 2021 at IGC Pharma, down from $1.8 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.8 million in Q4 2020 to a low of -$3.0 million in Q1 2021.
  • A 4-year average of -$185970.8 and a median of $2053.0 in 2017 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: soared 106.42% in 2017, then tumbled 106.02% in 2018.
  • IGC Pharma's Change in Acquisitions & Divestments stood at $1764.0 in 2017, then crashed by 332.77% to -$4106.0 in 2018, then skyrocketed by 45156.02% to $1.8 million in 2020, then crashed by 264.0% to -$3.0 million in 2021.
  • Per Business Quant, the three most recent readings for IGC's Change in Acquisitions & Divestments are -$3.0 million (Q1 2021), $1.8 million (Q4 2020), and -$4106.0 (Q1 2018).